142 related articles for article (PubMed ID: 20606838)
1. Imatinib-induced pancreatitis.
Varma MR; Mathew S; Krishnadas D; Vinayakumar KR
Indian J Pharmacol; 2010 Feb; 42(1):50-2. PubMed ID: 20606838
[TBL] [Abstract][Full Text] [Related]
2. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
Ikeda K; Shiga Y; Takahashi A; Kai T; Kimura H; Takeyama K; Noji H; Ogawa K; Nakamura A; Ohira H; Sato Y; Maruyama Y
Leuk Lymphoma; 2006 Jan; 47(1):155-7. PubMed ID: 16321842
[TBL] [Abstract][Full Text] [Related]
3. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
4. Acute pancreatitis in a patient treated with imatinib and gefitinib.
Escudero-Vilaplana V; Collado-Borrell R; Villanueva-Bueno C; Álvarez R; Herranz A; Sanjurjo M
J Oncol Pharm Pract; 2021 Jun; 27(4):980-983. PubMed ID: 32799779
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate-induced acute hepatotoxicity.
Frikha I; Fakhfakh Y; Sahnoun R; Chtourou L; Medhaffar M; Elloumi M
J Oncol Pharm Pract; 2023 Dec; 29(8):2027-2030. PubMed ID: 37464887
[TBL] [Abstract][Full Text] [Related]
6. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Smith BD; Kasamon YL; Kowalski J; Gocke C; Murphy K; Miller CB; Garrett-Mayer E; Tsai HL; Qin L; Chia C; Biedrzycki B; Harding TC; Tu GH; Jones R; Hege K; Levitsky HI
Clin Cancer Res; 2010 Jan; 16(1):338-47. PubMed ID: 20048335
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
Belgaumi AF; Al-Shehri A; Ayas M; Al-Mahr M; Al-Seraihy A; Al-Ahmari A; El-Solh H
Haematologica; 2010 Jul; 95(7):1211-5. PubMed ID: 20410182
[TBL] [Abstract][Full Text] [Related]
8. Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate.
Sung Y; Kim MH; Cho E
J Cosmet Laser Ther; 2019; 21(4):243-244. PubMed ID: 30285513
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
11. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y
Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828
[TBL] [Abstract][Full Text] [Related]
12. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
[TBL] [Abstract][Full Text] [Related]
13. Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
Akay OM; Mutlu F; Gülbaş Z
Turk J Haematol; 2016 Jun; 33(2):127-30. PubMed ID: 26377244
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
15. Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia.
Albayrak M; Celebi H; Albayrak A; Can ES; Aslan V; Onec B; Coban I
Eurasian J Med; 2011 Dec; 43(3):192-5. PubMed ID: 25610192
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
17. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
18. Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia.
Kassar O; Kahla AB; Koubaa A; Kallel F; Amor IB; Elloumi M
J Oncol Pharm Pract; 2023 Jun; 29(4):996-998. PubMed ID: 36344191
[TBL] [Abstract][Full Text] [Related]
19. Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Go SW; Kim BK; Lee SH; Kim TJ; Huh JY; Lee JM; Hah JH; Kim DW; Cho MJ; Kim TW; Kang JY
Tuberc Respir Dis (Seoul); 2013 Dec; 75(6):256-9. PubMed ID: 24416057
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate.
Batra J; Ankireddypalli AR; Kanugula AK; Gorle S; Kaur J
Cureus; 2023 Jun; 15(6):e40368. PubMed ID: 37325683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
